Search

Your search keyword '"Dreicer, Robert"' showing total 1,095 results
Start Over Author "Dreicer, Robert"
1,095 results on '"Dreicer, Robert"'

51. Supplementary Tables S1-S2 from Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

Author

Ko, Jennifer S., primary, Zea, Arnold H., primary, Rini, Brian I., primary, Ireland, Joanna L., primary, Elson, Paul, primary, Cohen, Peter, primary, Golshayan, Ali, primary, Rayman, Patricia A., primary, Wood, Laura, primary, Garcia, Jorge, primary, Dreicer, Robert, primary, Bukowski, Ronald, primary, and Finke, James H., primary

Published
2023
Full Text
View/download PDF

52. First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer.

Author

Mucci, Lorelei A, primary, Vinson, Jake, additional, Gerke, Travis A., additional, Hyslop, Terry, additional, Howard, Lauren, additional, Dreicer, Robert, additional, Rathkopf, Dana E., additional, Chi, Kim N., additional, Esteban, Emilio, additional, Enting, Deborah, additional, Bjartell, Anders, additional, Tagawa, Scott T., additional, Nanus, David M., additional, Ong, Michael, additional, Barata, Pedro C., additional, Hotte, Sebastien J., additional, Grant, Marie, additional, Villanti, Paul, additional, Kantoff, Philip W., additional, and George, Daniel J., additional

Published
2023
Full Text
View/download PDF

53. EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma

Author

Sadeghi, Sarmad, primary, Quinn, David, additional, Dorff, Tanya, additional, Pal, Sumanta, additional, Groshen, Susan, additional, Tsao-Wei, Denice, additional, Parikh, Rahul, additional, Devitt, Michael, additional, Parikh, Mamta, additional, Jackovich, Alexandra, additional, Ruel, Nora, additional, Vogelzang, Nicholas, additional, Burgess, Earle, additional, Siddiqi, Imran, additional, Gill, Inderbir S., additional, Lara, Primo N., additional, Dreicer, Robert, additional, and Gill, Parkash S., additional

Published
2023
Full Text
View/download PDF

54. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Author

Rosenberg, Jonathan E, Hoffman-Censits, Jean, Powles, Tom, van der Heijden, Michiel S, Balar, Arjun V, Necchi, Andrea, Dawson, Nancy, O'Donnell, Peter H, Balmanoukian, Ani, Loriot, Yohann, Srinivas, Sandy, Retz, Margitta M, Grivas, Petros, Joseph, Richard W, Galsky, Matthew D, Fleming, Mark T, Petrylak, Daniel P, Perez-Gracia, Jose Luis, Burris, Howard A, Castellano, Daniel, Canil, Christina, Bellmunt, Joaquim, Bajorin, Dean, Nickles, Dorothee, Bourgon, Richard, Frampton, Garrett M, Cui, Na, Mariathasan, Sanjeev, Abidoye, Oyewale, Fine, Gregg D, and Dreicer, Robert

Published
2016
Full Text
View/download PDF

55. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233

Author

Mitin, Timur, George, Asha, Zietman, Anthony L., Heney, Niall M., Kaufman, Donald S., Uzzo, Robert G., Dreicer, Robert, Wallace, H. James, III, Souhami, Luis, Dobelbower, M. Chris, Sandler, Howard M., and Shipley, William U.

Published
2016
Full Text
View/download PDF

56. Additional file 1 of CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment

Author

Li, Jun, Huang, Tao, Hua, Jun, Wang, Qiong, Su, Yang, Chen, Ping, Bidlingmaier, Scott, Li, Allan, Xie, Zhongqiu, Bidkar, Anil P., Shen, Sui, Shi, Weibin, Seo, Youngho, Flavell, Robert R., Gioeli, Daniel, Dreicer, Robert, Li, Hui, Liu, Bin, and He, Jiang

Abstract

Additional file 1: Table S1. Hematology parameters of acute (day-14) and long-term (day-90) toxicity studies. RBC: Red blood cell; WBC: White blood cell; PLT: Platelet; HCT: Hematocrit test (proportion of RBC in blood); HGB: Hemoglobin; Neu: Neutrophil; Lym: Lymphocyte; Mon: Monocyte; and Eos: Eosinophil. Mean ± SD, n = 5. Table S2. Blood clinical chemistry tests for liver and kidney function for acute and long-term toxicity studies. Figure S1. The calibration curve of Pb-Arsenazo (Pb-AAIII) spectrophotometric assay for determining the TCMC chelator number per antibody. The standard curve of UV (upper panel) is constructed by plotting the absorbance at 656 nm against Pb2+ concentration at various dilutions from a stock solution of Pb(II)-AA(III). The stock solution was prepared in a 0.15 M NH4OAc buffer at pH 7.0, containing 10 mM AAIII and 4.83 mM Pb(II).. The titration curve (bottom panel) is constructed by plotting the change of UV absorbance at 656 nm (%) against the mass of TCMC added to 100 µl of the Pb(II)-AA(III) complex solution. The solution had a Pb2+ concentration of 192 µM. Figure S2. Therapeutic effects of a single dose 212Pb-TCMC-YS5 in the PC3 subcutaneous CDX model. Tumor growth of individual mice within 55 days post treatment of 212Pb-TCMC-YS5 (normalized against tumor volume at day 0). Red: Study group receiving 212Pb-TCMC-YS5. Blue: Control group receiving unlabeled YS5 antibody only. Figure S3. BLI images of the PC3-Luc orthotropic CDX model treated by a single dose 212Pb-TCMC-YS5 (top), and the cold YS5 control (bottom). Two animals died in the control group on day-19 post treatment and were not imaged. Figure S4: Change (days post injection) of actual tumor volume of individual PDX mouse treated with a single dose of 0.37MBq (10 μCi) and 0.74 MBq (20 μCi) of 212Pb-TCMC-YS5.

Published
2023
Full Text
View/download PDF

59. Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma

Author

Sonpavde, Guru, Pond, Gregory R., Rosenberg, Jonathan E., Bajorin, Dean F., Regazzi, Ashley M., Choueiri, Toni K., Qu, Angela Q., Niegisch, Guenter, Albers, Peter, Necchi, Andrea, Di Lorenzo, Giuseppe, Fougeray, Ronan, Dreicer, Robert, Chen, Yu-Hui, Wong, Yu-Ning, Sridhar, Srikala S., Ko, Yoo-Joung, Milowsky, Matthew I., Galsky, Matthew D., and Bellmunt, Joaquim

Published
2015
Full Text
View/download PDF

60. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial

Author

Saad, Fred, Fizazi, Karim, Jinga, Viorel, Efstathiou, Eleni, Fong, Peter C, Hart, Lowell L, Jones, Robert, McDermott, Raymond, Wirth, Manfred, Suzuki, Kazuhiro, MacLean, David B, Wang, Ling, Akaza, Hideyuki, Nelson, Joel, Scher, Howard I, Dreicer, Robert, Webb, Iain J, and de Wit, Ronald

Published
2015
Full Text
View/download PDF

61. CD46 targeted212Pb alpha particle radioimmunotherapy for prostate cancer treatment

Author

Li, Jun, primary, Huang, Tao, additional, Hua, Jun, additional, Wang, Qiong, additional, Su, Yang, additional, Chen, Ping, additional, Bidlingmaier, Scott, additional, Li, Allan, additional, Xie, Zhongqiu, additional, Bidkar, Anil, additional, Shen, Sui, additional, Shi, Weibin, additional, Seo, Youngho, additional, Flavell, Robert R., additional, Gioeli, Daniel, additional, Dreicer, Robert, additional, Li, Hui, additional, Liu, Bin, additional, and He, Jiang, additional

Published
2022
Full Text
View/download PDF

66. Innovations in Prostate Cancer Management: Taking a Personalized Approach to Optimal Treatment.

Author

Dreicer, Robert

Subjects
THERAPEUTIC use of antineoplastic agents, DRUG efficacy, ANTIANDROGENS, TESTOSTERONE, INDIVIDUALIZED medicine, CONTINUING education units, METASTASIS, MEDICAL protocols, CASTRATION-resistant prostate cancer, GENOMICS, HEALTH care teams, POSITRON emission tomography, PROSTATE-specific antigen, PROSTATE tumors, DISEASE management
Published
2023

68. A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Author

Vaishampayan, Ulka N., primary, Keessen, Marianne, additional, Heath, Elisabeth I., additional, Dreicer, Robert, additional, Buchler, Tomas, additional, Árkosy, Péter Ferenc, additional, Csoszi, Tibor, additional, Wiechno, Pawel J., additional, Kholtobin, Denis, additional, Kopyltsov, Evgeny, additional, Shore, Neal D., additional, Nosov, Aleander, additional, Orlov, Sergey, additional, Plekhanov, Alexey, additional, Smagina, Maria, additional, Varlamov, Sergey, additional, and Vogelzang, Nicholas J., additional

Published
2022
Full Text
View/download PDF

69. Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

Author

Tripathi, Abhishek, primary, Chen, Yu-Hui, additional, Jarrard, David Frazier, additional, Hahn, Noah M., additional, Garcia, Jorge A., additional, Dreicer, Robert, additional, Liu, Glenn, additional, Hussain, Maha H. A., additional, Shevrin, Daniel H., additional, Cooney, Matthew M., additional, Eisenberger, Mario A., additional, Kohli, Manish, additional, Plimack, Elizabeth R., additional, Vogelzang, Nicholas J., additional, Picus, Joel, additional, Carducci, Michael Anthony, additional, DiPaola, Robert S., additional, and Sweeney, Christopher, additional

Published
2022
Full Text
View/download PDF

70. Phase 3 VERACITY clinical study of sabizabulin in men with metastatic castration-resistant prostate cancer who have progressed on an androgen receptor targeting agent.

Author

Dreicer, Robert, primary, Chu, Franklin, additional, Cahn, David J, additional, Getzenberg, Robert H., additional, Rodriguez, Domingo, additional, Barnette, K. Gary, additional, Steiner, Mitchell S., additional, Saltzstein, Daniel R., additional, Tutrone, Ronald F., additional, and Shore, Neal D., additional

Published
2022
Full Text
View/download PDF

71. BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.

Author

Hussain, Maha H. A., primary, Kocherginsky, Masha, additional, Agarwal, Neeraj, additional, Zhang, Jingsong, additional, Adra, Nabil, additional, Paller, Channing Judith, additional, Picus, Joel, additional, Reichert, Zachery R, additional, Szmulewitz, Russell Zelig, additional, Tagawa, Scott T., additional, Whang, Young E., additional, Dreicer, Robert, additional, Kuzel, Timothy, additional, Bazzi, Latifa, additional, Gerke, Travis A., additional, Daignault-Newton, Stephanie, additional, Chinnaiyan, Arul, additional, and Antonarakis, Emmanuel S., additional

Published
2022
Full Text
View/download PDF

74. Prospective Clinical Study of Precision Oncology in Solid Tumors

Author

Sohal, Davendra P. S., Rini, Brian I., Khorana, Alok A., Dreicer, Robert, Abraham, Jame, Procop, Gary W., Saunthararajah, Yogen, Pennell, Nathan A., Stevenson, James P., Pelley, Robert, Estfan, Bassam, Shepard, Dale, Funchain, Pauline, Elson, Paul, Adelstein, David J., and Bolwell, Brian J.

Published
2016
Full Text
View/download PDF

76. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer

Author

Li, Zhenfei, Bishop, Andrew C., Alyamani, Mohammad, Garcia, Jorge A., Dreicer, Robert, Bunch, Dustin, Liu, Jiayan, Upadhyay, Sunil K., Auchus, Richard J., and Sharifi, Nima

Subjects
Cytochrome P-450 -- Analysis, Antiandrogens -- Analysis, Abiraterone -- Health aspects, Prostate cancer -- Drug therapy, Isoenzymes -- Analysis, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability of converting precursor steroids to 5a-dihydrotestosterone (DHT), promoting signalling by the androgen receptor and the development of castration-resistant prostate cancer (1-3). Essential for resistance, DHT synthesis from adrenal precursor steroids or possibly from de novo synthesis from cholesterol commonly requires enzymatic reactions by 3[beta]-hydroxysteroid dehydrogenase (3[beta]HSD), steroid-5[alpha]-reductase (SRD5A) and 17[beta]-hydroxysteroid dehydrogenase (17[beta]HSD) isoenzymes (4,5). Abiraterone, a steroidal 17a-hydroxylase/17,20-lyase (CYP17A1) inhibitor, blocks this synthetic process and prolongs survival (6,7). We hypothesized that abiraterone is converted by an enzyme to the more active [[DELTA].sup.4]-abiraterone (D4A), which blocks multiple steroidogenic enzymes and antagonizes the androgen receptor, providing an additional explanation for abiraterone's clinical activity. Here we show that abiraterone is converted to D4A in mice and patients with prostate cancer. D4A inhibits CYP17A1, 3[beta]HSD and SRD5A, which are required for DHT synthesis. Furthermore, competitive androgen receptor antagonism by D4A is comparable to the potent antagonist enzalutamide. D4A also has more potent anti-tumour activity against xenograft tumours than abiraterone. Our findings suggest an additional explanation--conversion to a more active agent--for abiraterone's survival extension. We propose that direct treatment with D4A would be more clinically effective than abiraterone treatment., The central role and critical requirement for androgen metabolism and androgen receptor (AR) in castration-resistant prostate cancer (CRPC) are demonstrated by the clinical benefit and overall survival benefit conferred by [...]

Published
2015

77. CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment.

Author

Li, Jun, Huang, Tao, Hua, Jun, Wang, Qiong, Su, Yang, Chen, Ping, Bidlingmaier, Scott, Li, Allan, Xie, Zhongqiu, Bidkar, Anil P., Shen, Sui, Shi, Weibin, Seo, Youngho, Flavell, Robert R., Gioeli, Daniel, Dreicer, Robert, Li, Hui, Liu, Bin, and He, Jiang

Subjects
PROSTATE cancer, ALPHA rays, CASTRATION-resistant prostate cancer, CD46 antigen, CELL surface antigens, RADIOIMMUNOTHERAPY, LEAD compounds, ERIBULIN
Abstract

We recently identified CD46 as a novel prostate cancer cell surface antigen that shows lineage independent expression in both adenocarcinoma and small cell neuroendocrine subtypes of metastatic castration resistant prostate cancer (mCRPC), discovered an internalizing human monoclonal antibody YS5 that binds to a tumor selective CD46 epitope, and developed a microtubule inhibitor-based antibody drug conjugate that is in a multi-center phase I trial for mCRPC (NCT03575819). Here we report the development of a novel CD46-targeted alpha therapy based on YS5. We conjugated 212Pb, an in vivo generator of alpha-emitting 212Bi and 212Po, to YS5 through the chelator TCMC to create the radioimmunoconjugate, 212Pb-TCMC-YS5. We characterized 212Pb-TCMC-YS5 in vitro and established a safe dose in vivo. We next studied therapeutic efficacy of a single dose of 212Pb-TCMC-YS5 using three prostate cancer small animal models: a subcutaneous mCRPC cell line-derived xenograft (CDX) model (subcu-CDX), an orthotopically grafted mCRPC CDX model (ortho-CDX), and a prostate cancer patient-derived xenograft model (PDX). In all three models, a single dose of 0.74 MBq (20 µCi) 212Pb-TCMC-YS5 was well tolerated and caused potent and sustained inhibition of established tumors, with significant increases of survival in treated animals. A lower dose (0.37 MBq or 10 µCi 212Pb-TCMC-YS5) was also studied on the PDX model, which also showed a significant effect on tumor growth inhibition and prolongation of animal survival. These results demonstrate that 212Pb-TCMC-YS5 has an excellent therapeutic window in preclinical models including PDXs, opening a direct path for clinical translation of this novel CD46-targeted alpha radioimmunotherapy for mCRPC treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

79. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Author

Gao, Xin, primary, Burris III, Howard A., additional, Vuky, Jacqueline, additional, Dreicer, Robert, additional, Sartor, A. Oliver, additional, Sternberg, Cora N., additional, Percent, Ivor John, additional, Hussain, Maha H. A., additional, Rezazadeh Kalebasty, Arash, additional, Shen, John, additional, Heath, Elisabeth I., additional, Abesada-Terk, Guillermo, additional, Gandhi, Sunil G., additional, McKean, Meredith, additional, Lu, Haolan, additional, Berghorn, Elmer, additional, Gedrich, Richard, additional, Chirnomas, S. Debbie, additional, Vogelzang, Nicholas J., additional, and Petrylak, Daniel P., additional

Published
2022
Full Text
View/download PDF

80. Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial).

Author

Reichert, Zachery R, primary, Devitt, Michael Edward, additional, Alumkal, Joshi J., additional, Smith, David C., additional, Caram, Megan Veresh, additional, Palmbos, Philip, additional, Vaishampayan, Ulka N., additional, Alva, Ajjai Shivaram, additional, Braun, Thomas, additional, Yentz, Sarah Elizabeth, additional, Tsao, Phoebe A., additional, Dreicer, Robert, additional, Cackowski, Frank Cameron, additional, Shah, Neel, additional, Dean, Emma, additional, Smith, Simon, additional, and Heath, Elisabeth I., additional

Published
2022
Full Text
View/download PDF

81. Phase 2 randomized trial of ModraDoc006/r, oral docetaxel plus ritonavir, versus intravenous docetaxel in metastatic castration resistant prostate cancer (mCRPC).

Author

Vaishampayan, Ulka N., primary, Keessen, Marianne, additional, Shore, Neal D., additional, Heath, Elisabeth I., additional, Dreicer, Robert, additional, Buchler, Tomas, additional, Árkosy, Péter Ferenc, additional, Csoszi, Tibor, additional, Wiechno, Pawel J., additional, Kopyltsov, Evgeny, additional, Kholtobin, Denis, additional, Orlov, Sergey, additional, Nosov, Aleander, additional, Varlamov, Sergey, additional, and Vogelzang, Nicholas J., additional

Published
2022
Full Text
View/download PDF

87. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

Author

Pal, Sumanta K., primary, McGregor, Bradley, additional, Suárez, Cristina, additional, Tsao, Che-Kai, additional, Kelly, William, additional, Vaishampayan, Ulka, additional, Pagliaro, Lance, additional, Maughan, Benjamin L., additional, Loriot, Yohann, additional, Castellano, Daniel, additional, Srinivas, Sandy, additional, McKay, Rana R., additional, Dreicer, Robert, additional, Hutson, Thomas, additional, Dubey, Sarita, additional, Werneke, Scott, additional, Panneerselvam, Ashok, additional, Curran, Dominic, additional, Scheffold, Christian, additional, Choueiri, Toni K., additional, and Agarwal, Neeraj, additional

Published
2021
Full Text
View/download PDF

88. Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma

Author

Pal, Sumanta K., primary, Frankel, Paul H., additional, Mortazavi, Amir, additional, Milowsky, Matthew, additional, Vaishampayan, Ulka, additional, Parikh, Mamta, additional, Lyou, Yung, additional, Weng, Peng, additional, Parikh, Rahul, additional, Teply, Benjamin, additional, Dreicer, Robert, additional, Emamekhoo, Hamid, additional, Michaelson, Dror, additional, Hoimes, Christopher, additional, Zhang, Tian, additional, Srinivas, Sandy, additional, Kim, William Y., additional, Cui, Yujie, additional, Newman, Edward, additional, and Lara, Primo N., additional

Published
2021
Full Text
View/download PDF

89. PRIMARY ANALYSIS OF IMVIGOR 210: ATEZOLIZUMAB IN PLATINUM-TREATED ADVANCED UROTHELIAL CARCINOMA: PD27-12

Author

Dreicer, Robert, van der Heijden, Michiel S., Grivas, Petros, Hoffman-Censits, Jean, Loriot, Yohann, Retz, Margitta, Vogelzang, Nicholas J, Perez-Gracia, Jose Luis, Kalebasty, Arash Rezazadeh, Bracarda, Sergio, Yu, Evan Y, Hoimes, Christopher, Bellmunt, Joaquim, Quinn, David I, Petrylak, Daniel P., Hussain, Syed A, Cui, Na, Mariathasan, Sanjeev, Legrand, Fatema, and Rosenberg, Jonathan E.

Published
2016
Full Text
View/download PDF

91. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

Author

Rosenberg, Jonathan E., primary, Ballman, Karla A., additional, Halabi, Susan, additional, Atherton, Pamela J., additional, Mortazavi, Amir, additional, Sweeney, Christopher, additional, Stadler, Walter M., additional, Teply, Benjamin A., additional, Picus, Joel, additional, Tagawa, Scott T., additional, Katragadda, Sreedhar, additional, Vaena, Daniel, additional, Misleh, Jamal, additional, Hoimes, Christopher, additional, Plimack, Elizabeth R., additional, Flaig, Thomas W., additional, Dreicer, Robert, additional, Bajorin, Dean, additional, Hahn, Olwen, additional, Small, Eric J., additional, and Morris, Michael J., additional

Published
2021
Full Text
View/download PDF

92. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Author

Powles, Thomas, primary, Csőszi, Tibor, additional, Özgüroğlu, Mustafa, additional, Matsubara, Nobuaki, additional, Géczi, Lajos, additional, Cheng, Susanna Y-S, additional, Fradet, Yves, additional, Oudard, Stephane, additional, Vulsteke, Christof, additional, Morales Barrera, Rafael, additional, Fléchon, Aude, additional, Gunduz, Seyda, additional, Loriot, Yohann, additional, Rodriguez-Vida, Alejo, additional, Mamtani, Ronac, additional, Yu, Evan Y, additional, Nam, Kijoeng, additional, Imai, Kentaro, additional, Homet Moreno, Blanca, additional, Alva, Ajjai, additional, Cascallar, Diana Vera, additional, Varela, Mirta, additional, Lazzaro, Mauricio Fernandez, additional, Kaen, Diego Lucas, additional, Gatica, Gabriela, additional, Flores, David Hugo, additional, Falco, Agustin, additional, Molina, Matias, additional, Van Aelst, Filip, additional, Sautois, Brieuc, additional, Machiels, Jean-Pascal, additional, Schallier, Denis, additional, Brust, Leandro, additional, Rapatoni, Liane, additional, Azevedo, Sergio J, additional, Marinho, Gisele, additional, Soares, Joao Paulo Holanda, additional, Dzik, Carlos, additional, Almeida Silva, Jamile, additional, Fay, Andre Poisl, additional, Gingerich, Joel, additional, Ferrario, Cristiano, additional, Potvin, Kylea, additional, Vanhuyse, Marie, additional, Abdelsalam, Mahmoud, additional, Cheng, Susanna, additional, Caglevic, Christian, additional, Reyes, Felipe, additional, Leal, Jose Luis, additional, Francisco, Francisco, additional, Ibanez, Carolina, additional, Joly, Florence, additional, Laguerre, Brigitte, additional, Ladoire, Sylvain, additional, Flechon, Aude, additional, Topart, Delphine, additional, Huillard, Olivier, additional, Oudard, Stéphane, additional, Gross-Goupil, Marine, additional, Culine, Stephane, additional, Gravis, Gwenaelle, additional, Reichardt, Peter, additional, Retz, Margitta, additional, Herden, Jan, additional, Pfister, David, additional, Ohlman, Carsten, additional, Stoeckle, Michael, additional, Wirth, Manfred, additional, Lorch, Anja, additional, Niegisch, Guenter, additional, Goebell, Peter J, additional, Boegemann, Martin, additional, Merseburger, Axel, additional, Gakis, Georgios, additional, Bedke, Jens, additional, Neisius, Andreas, additional, Thomas, Christian, additional, Hoefner, Thomas, additional, Telekes, Andras, additional, Kosa, Judit Erzsebet, additional, Revesz, Janos, additional, Bodoky, Gyorgy, additional, Csoszi, Tibor, additional, Csejtei, Andras, additional, Geczi, Lajos, additional, Ruzsa, Agnes, additional, Kolonics, Zsuzsanna, additional, Erfan, Jozsef, additional, McDermott, Ray, additional, Bambury, Richard, additional, Sella, Avishay, additional, Frank, Stephen Jay, additional, Kejzman, Daniel, additional, Goldman, Olesya, additional, Rosenbaum, Eli, additional, Peer, Avivit, additional, Berger, Raanan, additional, Rouvinov, Keren, additional, Sarid, David, additional, Fukasawa, Satoshi, additional, Arai, Gaku, additional, Yamaguchi, Akito, additional, Yokomizo, Akira, additional, Takayama, Tatsuya, additional, Kinoshita, Hidefumi, additional, Kikuchi, Eiji, additional, Mizuno, Ryuichi, additional, Fujii, Yasuhisa, additional, Sassa, Naoto, additional, Matsukawa, Yoshihisa, additional, Fujimoto, Kiyohide, additional, Tanikawa, Toshiki, additional, Tomita, Yoshihiko, additional, Nishimura, Kazuo, additional, Tsujihata, Masao, additional, Oyama, Masafumi, additional, Masumori, Naoya, additional, Kanayama, Hiroomi, additional, Takano, Toshimi, additional, Miura, Yuji, additional, Miyazaki, Jun, additional, Joraku, Akira, additional, Kimura, Tomokazu, additional, Yamamoto, Yoshiaki, additional, Kobayashi, Kazuki, additional, De Wit, Ronald, additional, Aarts, Maureen, additional, Gerritsen, Winald, additional, Los, Maartje, additional, Beerepoot, Laurens, additional, Izmailov, Adel, additional, Gorelov, Sergey Igorevich, additional, Alekseev, Boris Yakovlevich, additional, Semenov, Andrey, additional, Kostorov, Vladimir Anatolyevich, additional, Alekseev, Sergey M, additional, Zyryanov, Alexander, additional, Oschepkov, Vasiliy Nikolaevich, additional, Shidin, Vladimir Aleksandrovich, additional, Vladimirov, Vladimir Ivanovich, additional, Gafanov, Rustem Airatovich, additional, Karlov, Petr Alexandrovich, additional, Anderson, David Brian, additional, Shepherd, Lucinda, additional, Cohen, Graham Lawrence, additional, Rapoport, Bernardo Louis, additional, Ruff, Paul, additional, Lee, Nari, additional, Bae, Woo Kyun, additional, Lee, Hyo Jin, additional, Herranz, Urbano Anido, additional, Grande, Enrique, additional, Alonso Gordoa, Teresa, additional, Guma Padro, Josep, additional, Gauna, Daniel Castellano, additional, Arranz, Jose Angel, additional, Munoz Langa, Jose, additional, Sarrio, Regina Girones, additional, Montesa Pino, Alvaro, additional, Juan Fita, Maria Jose, additional, Su, Yu-Li, additional, Lin, Yung-Chang, additional, Su, Wen-Pin, additional, Shen, Ying-Chun, additional, Chang, Yen-Hwa, additional, Huang, Yi-Hsiu, additional, Sriuranpong, Virote, additional, Chansriwong, Phichai, additional, Srimuninnimit, Vichien, additional, Danchaivijitr, Pongwut, additional, Abali, Huseyin, additional, Yavuz, Sinan, additional, Ozyilkan, Ozgur, additional, Sendur, Mehmet Ali Nahit, additional, Ekenel, Meltem, additional, Ozguroglu, Mustafa, additional, Arslan, Cagatay, additional, Ozdogan, Mustafa, additional, Birtle, Alison, additional, Powles, Thomas, additional, Huddart, Robert, additional, de Santis, Maria, additional, Zarkar, Anjali, additional, Evans, Linda, additional, Hussain, Syed, additional, DiSimone, Christopher, additional, Muina, Antonio F, additional, Schlegel, Peter, additional, Jhangiani, Haresh S, additional, Harrison, Michael, additional, Slater, Dennis E, additional, Wright, David, additional, Percent, Ivor J, additional, Lin, Jianqing, additional, Hwang, Clara, additional, Gupta, Sumati, additional, Bajaj, Madhuri, additional, Galamaga, Robert, additional, Eklund, John, additional, Wallace, James, additional, Shtivelband, Mikhail, additional, Suh, Jason Jung-Gon, additional, Burhani, Nafisa, additional, Eadens, Matthew, additional, Gunturu, Krishna, additional, Burgess, Earle, additional, Wong, John, additional, Chaudhry, Arvind, additional, Van Veldhuizen, Peter, additional, Graff, Stephanie, additional, Thomas, Christian A, additional, Schnadig, Ian D, additional, Carneiro, Benedito, additional, Hussain, Maha, additional, Morgans, Alicia, additional, Fitzharris, John T, additional, Oliff, Ira A, additional, Vuky, Jacqueline, additional, Hauke, Ralph, additional, Baron, Ari, additional, Joshi, Monika, additional, Bolemon, Britt H, additional, Jiang, Peter, additional, Mega, Anthony E, additional, Markus, Maurice, additional, Pfanzelter, Nicklas, additional, Lawler, William Eyre, additional, Cobb, Patrick Wayne, additional, Courtright, Jay G, additional, Jain, Sharad, additional, Doshi, Gurjyot, additional, Gunuganti, Vijay K, additional, Sartor, Oliver Alton, additional, Cole, Scott W, additional, Babiker, Hani, additional, Uchio, Edward M, additional, Drakaki, Alexandra, additional, Mannuel, Heather D, additional, Guancial, Elizabeth, additional, Fung, Chunkit, additional, Charles, Anthony, additional, Amato, Robert J, additional, Arriaga, Yull, additional, Bowman, Isaac, additional, Ades, Steven, additional, Dreicer, Robert, additional, Yu, Evan, additional, Quinn, David I, additional, and Fleming, Mark, additional

Published
2021
Full Text
View/download PDF

97. Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805.

Author

Morgans, Alicia K., Chen, Yu‐Hui, Jarrard, David F., Carducci, Michael, Liu, Glenn, Eisenberger, Mario, Plimack, Elizabeth R., Bryce, Alan, Garcia, Jorge A., Dreicer, Robert, Vogelzang, Nicholas J., Picus, Joel, Shevrin, Daniel, Hussain, Maha, DiPaola, Robert S., Cella, David, and Sweeney, Christopher J.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results